Terms: = Breast cancer AND SYK, P43405, 6850, ENSG00000165025 AND Treatment
22 results:
1. A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
Juric D; Barve M; Vaishampayan U; Roda D; Calvo A; Jañez NM; Trigo J; Greystoke A; Harvey RD; Olszanski AJ; Opyrchal M; Spira A; Thistlethwaite F; Jiménez B; Sappal JH; Kannan K; Riley J; Li C; Li C; Gregory RC; Miao H; Wang S
Cancer Med; 2024 Mar; 13(5):. PubMed ID: 38501219
[TBL] [Abstract] [Full Text] [Related]
2. Combination of bendamustine-azacitidine against syk target of breast cancer: an
Muthumanickam S; Ramachandran B; Boomi P; Jeyakanthan J; Prabu HG; Jegatheswaran S; Premkumar K
J Biomol Struct Dyn; 2023; 41(23):13950-13962. PubMed ID: 37098715
[TBL] [Abstract] [Full Text] [Related]
3. Tumor cell syk expression modulates the tumor immune microenvironment composition in human cancer via TNF-α dependent signaling.
Aguirre-Ducler A; Gianino N; Villarroel-Espindola F; Desai S; Tang D; Zhao H; Syrigos K; Trepicchio WL; Kannan K; Gregory RC; Schalper KA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35868661
[TBL] [Abstract] [Full Text] [Related]
4. American Joint Committee on cancer Tumor Staging System Predicts the Outcome and Metastasis Pattern in Conjunctival Melanoma.
Jia S; Zhu T; Shi H; Zong C; Bao Y; Wen X; Ge S; Ruan J; Xu S; Jia R; Fan X
Ophthalmology; 2022 Jul; 129(7):771-780. PubMed ID: 35245602
[TBL] [Abstract] [Full Text] [Related]
5. DOCK2 regulates antifungal immunity by regulating RAC GTPase activity.
Ma X; Tan X; Yu B; Sun W; Wang H; Hu H; Du Y; He R; Gao R; Peng Q; Cui Z; Pan T; Feng X; Wang J; Xu C; Zhu B; Liu W; Wang C
Cell Mol Immunol; 2022 May; 19(5):602-618. PubMed ID: 35079145
[TBL] [Abstract] [Full Text] [Related]
6. A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age.
Yu J; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
J Transl Med; 2021 Feb; 19(1):75. PubMed ID: 33593381
[TBL] [Abstract] [Full Text] [Related]
7. CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
Zhao ZM; Yost SE; Hutchinson KE; Li SM; Yuan YC; Noorbakhsh J; Liu Z; Warden C; Johnson RM; Wu X; Chuang JH; Yuan Y
BMC Cancer; 2019 Jan; 19(1):96. PubMed ID: 30665374
[TBL] [Abstract] [Full Text] [Related]
8. Identification of key genes and pathways associated with classical Hodgkin lymphoma by bioinformatics analysis.
Kuang Z; Guo L; Li X
Mol Med Rep; 2017 Oct; 16(4):4685-4693. PubMed ID: 28791394
[TBL] [Abstract] [Full Text] [Related]
9. DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and breast cancer (WEB) study.
Callahan CL; Wang Y; Marian C; Weng DY; Eng KH; Tao MH; Ambrosone CB; Nie J; Trevisan M; Smiraglia D; Edge SB; Shields PG; Freudenheim JL
Epigenetics; 2016 Sep; 11(9):643-652. PubMed ID: 27245195
[TBL] [Abstract] [Full Text] [Related]
10. Identification of Personalized Chemoresistance Genes in Subtypes of Basal-Like breast cancer Based on Functional Differences Using Pathway Analysis.
Wu T; Wang X; Li J; Song X; Wang Y; Wang Y; Zhang L; Li Z; Tian J
PLoS One; 2015; 10(6):e0131183. PubMed ID: 26126114
[TBL] [Abstract] [Full Text] [Related]
11. Targeting a cell state common to triple-negative breast cancers.
Muellner MK; Mair B; Ibrahim Y; Kerzendorfer C; Lechtermann H; Trefzer C; Klepsch F; Müller AC; Leitner E; Macho-Maschler S; Superti-Furga G; Bennett KL; Baselga J; Rix U; Kubicek S; Colinge J; Serra V; Nijman SM
Mol Syst Biol; 2015 Feb; 11(1):789. PubMed ID: 25699542
[TBL] [Abstract] [Full Text] [Related]
12. Modulation by syk of Bcl-2, calcium and the calpain-calpastatin proteolytic system in human breast cancer cells.
Fei B; Yu S; Geahlen RL
Biochim Biophys Acta; 2013 Oct; 1833(10):2153-64. PubMed ID: 23684705
[TBL] [Abstract] [Full Text] [Related]
13. Reactivation of syk gene by AZA suppresses metastasis but not proliferation of breast cancer cells.
Xia TS; Shi JP; Ding Q; Liu XA; Zhao Y; Liu YX; Xia JG; Wang S; Ding YB
Med Oncol; 2012 Jun; 29(2):448-53. PubMed ID: 21347717
[TBL] [Abstract] [Full Text] [Related]
14. The protein-tyrosine kinase syk interacts with TRAF-interacting protein TRIP in breast epithelial cells.
Zhou Q; Geahlen RL
Oncogene; 2009 Mar; 28(10):1348-56. PubMed ID: 19151749
[TBL] [Abstract] [Full Text] [Related]
15. The ERBB3 receptor in cancer and cancer gene therapy.
Sithanandam G; Anderson LM
Cancer Gene Ther; 2008 Jul; 15(7):413-48. PubMed ID: 18404164
[TBL] [Abstract] [Full Text] [Related]
16. Hypoxia regulates cross-talk between syk and Lck leading to breast cancer progression and angiogenesis.
Chakraborty G; Rangaswami H; Jain S; Kundu GC
J Biol Chem; 2006 Apr; 281(16):11322-31. PubMed ID: 16474166
[TBL] [Abstract] [Full Text] [Related]
17. syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells.
Lu J; Lin WH; Chen SY; Longnecker R; Tsai SC; Chen CL; Tsai CH
J Biol Chem; 2006 Mar; 281(13):8806-14. PubMed ID: 16431925
[TBL] [Abstract] [Full Text] [Related]
18. Reactivation of syk expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness.
Yuan Y; Liu H; Sahin A; Dai JL
Int J Cancer; 2005 Feb; 113(4):654-9. PubMed ID: 15455373
[TBL] [Abstract] [Full Text] [Related]
19. syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells.
Mahabeleshwar GH; Kundu GC
J Biol Chem; 2003 Feb; 278(8):6209-21. PubMed ID: 12477728
[TBL] [Abstract] [Full Text] [Related]
20. Structure-based design of novel anticancer agents.
Uckun FM; Sudbeck EA; Mao C; Ghosh S; Liu XP; Vassilev AO; Navara CS; Narla RK
Curr Cancer Drug Targets; 2001 May; 1(1):59-71. PubMed ID: 12188892
[TBL] [Abstract] [Full Text] [Related]
[Next]
